Improving HIV treatment options for youth

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The SAVVY Study focuses on enhancing viral suppression in adolescents and young adults living with HIV by optimizing their antiretroviral treatment choices. It employs CHOICE counseling to engage participants in shared decision-making regarding their preferred treatment options, including long-acting injectable antiretroviral therapies. The study addresses unique challenges faced by this population, such as cognitive development and psychosocial factors, to improve adherence and health outcomes. By providing tailored interventions and access to alternative treatment strategies, the study aims to significantly improve virologic outcomes for participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* prescribed ART,
* willing to sign informed consent (including communication with one's primary HIV provider)

Exclusion Criteria:

* Relevant drug resistance mutations (per medical record) that compromises activity of Cabotegravir (CBG) + rilpivirine (RPV)
* disallowed medications,
* pregnancy.
* Mental health, cognitive, or behavioral dysfunction that in the opinion of the site PI would impair participation;
* severe illness/hospitalization at the time of enrollment,
* plan to move away in the next 12 months.

Where it's running

• Johns Hopkins University
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Allison Agwu, MD, SCM — Johns Hopkins University
• Study coordinator: Allison Agwu, MD, SCM
• Email: ageorg10@jhmi.edu
• Phone: 410-614-3917

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventing cervical cancer in women with HPV and HIV in Karnataka, India

  This trial will test whether a six-month ASHA-Health program of group education, ASHA-supported one-on-one sessions, nutrition support, and life-skills training can reduce persistent high-risk HPV in women living with HIV.

  Recruiting at 3 sites University of California, Irvine · Bangalore, Karnataka and 3 other locations · NCT07209917

• Doravirine treatment for HIV-infected children under 12 years old

  This study is testing a new HIV treatment called doravirine in children under 12 to see if it's safe and effective for them.

  Recruiting at 13 sites Phase 2 Merck Sharp & Dohme LLC · Aurora, Colorado and 25 other locations · NCT04375800

• Psilocybin-assisted therapy to help adults with amblyopia see more clearly

  This study tests whether a single or small doses of psilocybin can boost the effectiveness of amblyopia treatment in adults.

  Recruiting Phase 1/2 Johns Hopkins University · Baltimore, Maryland · NCT07920081

• ReVIVE for mTBI: Using VR and therapy to help adults with mild traumatic brain injury

  This study tests a virtual reality therapy combined with standard psychotherapy to see if it can reduce PTSD symptoms and improve executive function in adults with mild traumatic brain injury.

  Recruiting Phase 1 Johns Hopkins University · Baltimore, Maryland · NCT07890337

• Social Connection Collective for older adults in subsidized housing

  A resident-led program in subsidized housing in Baltimore will try to build friendships and peer support among residents aged 62 and older to see if it’s feasible and if it reduces loneliness.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT07863583

• Oral Food Challenge After Starting Omalizumab in Food Allergy

  This trial tests whether omalizumab begins to help with food allergy within 2 to 4 weeks after starting treatment in people with a confirmed food allergy.

  Recruiting Phase 4 Johns Hopkins University · Baltimore, Maryland · NCT07845552

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.